Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atherosclerosis
Research from B.V. Howard and colleagues provide new insights into atherosclerosis
May 12th, 2008
"Context Individuals with diabetes are at increased risk for cardiovascular disease ( CVD), but more aggressive targets for risk factor control have not been tested. To compare progression of subclinical atherosclerosis in adults with type 2 diabetes treated to reach aggressive targets of low- density lipoprotein cholesterol ( LDL- C) of 70 mg/ dL or lower and systolic blood pressure ( SBP) of 115 mm Hg or lower vs standard targets of LDL- C of 100 mg/ dL or lower and SBP of 130 mm Hg or lower," scientists in the United States report. "Setting, and Participants A randomized, open- label, blinded- to- end point, 3- year trial from April 2003- July 2007 at 4 clinical...
Source: Biotech Business Week (2008-05-12)
|
